What is Myriad Genetics ROE % Adjusted to Book Value?
Myriad Genetics's ROE % for the quarter that ended in Dec. 2023 was -17.02%. Myriad Genetics's PB Ratio for the quarter that ended in Dec. 2023 was 2.20.
Myriad Genetics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -7.74%.
Myriad Genetics ROE % Adjusted to Book Value Historical Data
The historical data trend for Myriad Genetics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Myriad Genetics ROE % Adjusted to Book Value Chart
Competitive Comparison of Myriad Genetics's ROE % Adjusted to Book Value
For the Diagnostics & Research subindustry, Myriad Genetics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics's ROE % Adjusted to Book Value Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's ROE % Adjusted to Book Value falls into.
Myriad Genetics ROE % Adjusted to Book Value Calculation
Myriad Genetics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics ROE % Adjusted to Book Value Related Terms
Thank you for viewing the detailed overview of Myriad Genetics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Myriad Genetics (Myriad Genetics) Business Description
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MYGN has been successfully added to your 